Alzheimer's disease: Will advances made in the past turn the tide?

Annals of Pharmacotherapy

Volumn 41, Issue 9, 2007, Pages 1494-1496

  Semla, Todd P ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Bldg 37 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; FLURBIPROFEN; GALANTAMINE; HOMOTAURINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEMANTINE; NONSTEROID ANTIINFLAMMATORY AGENT; RIVASTIGMINE; TACRINE;

ALZHEIMER DISEASE; COGNITION; COMPUTER ASSISTED TOMOGRAPHY; DEMENTIA; DIAGNOSTIC ACCURACY; DRUG DOSE TITRATION; DRUG MECHANISM; HUMAN; LIVER TOXICITY; MEMORY; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SHORT SURVEY;

ALZHEIMER DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIPSYCHOTIC AGENTS; CHOLINESTERASE INHIBITORS; EXCITATORY AMINO ACID ANTAGONISTS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDANS; MEMANTINE; PIPERIDINES; TACRINE;

EID: 34548188703     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K182     Document Type: Short Survey

References (2)

1. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-3.
2. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291:317-24.